Howard Burris, MD, FACP, FASCO, president of clinical operations and chief medical officer of Sarah Cannon Research Institute, discusses the adoption of oncology biosimilars.
So the biosimilars, I think, will be rapidly adopted. We’re in a world where the new cancer drugs really sort of came along in a flood in the 1990s, so we’ve had experience with generics in that regard. We’ve had oral generics coming along for a while. I think the biosimilars are actually coming from some of the larger manufacturers. The idea of transitioning to that, I think, will flow well.